● Recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Condition: Diffuse Large B-Cell Lymphoma · Sponsor: AstraZeneca

PhasePhase 2

Planned participants80

Who can joinAll sexes, 65 Years to 99 Years

Healthy volunteersNo

About this study

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (57)

Research Site	Berkeley, California, United States	Withdrawn
Research Site	La Jolla, California, United States	Completed
Research Site	Orange, California, United States	Recruiting
Research Site	Stamford, Connecticut, United States	Withdrawn
Research Site	Jacksonville, Florida, United States	Active Not Recruiting
Research Site	Des Moines, Iowa, United States	Recruiting
Research Site	Lexington, Kentucky, United States	Withdrawn
Research Site	Beltsville, Maryland, United States	Active Not Recruiting
Research Site	Towson, Maryland, United States	Active Not Recruiting
Research Site	Detroit, Michigan, United States	Active Not Recruiting
Research Site	Sioux Falls, South Dakota, United States	Withdrawn
Research Site	Lubbock, Texas, United States	Active Not Recruiting

+ 45 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05952024